-

Agilent Increases Cash Dividend to 21 Cents Per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 21 cents per share of common stock, reflecting an 8% increase over the previous quarter. The quarterly dividend will be paid on Jan. 26, 2022 to all shareholders of record as of the close of business on Jan. 4, 2022.

The timing and amounts of future dividends are subject to determination and approval by Agilent’s board of directors.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the company’s dividend program and future payment obligations. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties are detailed in Agilent’s filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended July 31, 2021. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

Contacts

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

Media Contact:
Tom Beermann
+1 408 386 5892
tom.beermann@agilent.com

Agilent Technologies, Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Summary
Agilent increases quarterly dividend to 21 cents per share.
Release Versions
$Cashtags

Contacts

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

Media Contact:
Tom Beermann
+1 408 386 5892
tom.beermann@agilent.com

Social Media Profiles
More News From Agilent Technologies, Inc.

Agilent Showcases Cancer Research Solutions at AACR 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f...

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica...
Back to Newsroom